NCT01436968Phase 3Active not recruiting

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Study sponsor: Candel Therapeutics, Inc. · CADL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-08Actual

Enrollment · participants711Estimated

Source updated2025-07-30Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Prostate Cancer

Treatments or interventions studied

Aglatimagene besadenovec + valacyclovirBiologicalAlso known as AdV-tk, CAN-2409
Placebo + valacyclovirBiological

Primary outcomes · main study measures

measure: Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.; timeFrame: Assessed at each visit every 6 months through year 5 until event occurs.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history